<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04000906</url>
  </required_header>
  <id_info>
    <org_study_id>2018-01327-Nab-PIPAC</org_study_id>
    <nct_id>NCT04000906</nct_id>
  </id_info>
  <brief_title>PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis</brief_title>
  <acronym>Nab-PIPAC</acronym>
  <official_title>A Phase Ib Trial of Intraperitoneal Cisplatin and Nab-paclitaxel Administered by Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Advanced Malignancies Confined to the Peritoneal Cavity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase Ib trial including investigating the combination of nab-paclitaxel and cisplatin in&#xD;
      patients diagnosed with peritoneal carcinomatosis related to pancreatic, oeso-gastric,&#xD;
      ovarian cancer or primitive peritoneal mesothelioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase Ib trial investigating the combination of intraperitoneal Cisplatin (10.5 mg/m2) and&#xD;
      Nab-paclitaxel (escalated dose from 7.5 mg/m2 to 70 mg/m2) administered by pressurized&#xD;
      intraperitoneal aerosol chemotherapy (PIPAC) every 4-6 weeks for 3 cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximal tolerated dose (MTD) of Nab paclitaxel (Abraxane®) administered IP by PIPAC in concomitance with cisplatin.</measure>
    <time_frame>From the time of treatment randomization through 30 days following cessation of treatment</time_frame>
    <description>MTD is defined as the lowest dose level at which ≥33% of patients' experience dose limiting toxicity in accordance to CTCAE version 5.0 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>D-1/D10 of each cycle</time_frame>
    <description>AE and SAE with predefined toxicity criteria will be applied using CTCAE version 5.0 criteria, documented before and after each cycle of PIPAC treatment. Surgical complications will be assessed according to Clavien classification and comprehensive complication index (CCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The efficacy</measure>
    <time_frame>D0 of each cycle</time_frame>
    <description>It will be assessed by the objective histological regression and objective tumor response rate (OTR) according to the new regression system for peritoneal cancer (PRGS, peritoneal regression grade score system). The objective response rate (ORR), the clinical benefit rate (CBR) as defined by RECIST version 1.1 criteria and the relevance of radiological response assessed by CT enterography (CT-PCI score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The QoL</measure>
    <time_frame>D-1/D10 of each cycle</time_frame>
    <description>QoL will be evaluated based on the EORTC questionnaire QLQ-C30 Version 3.0 and visual analogic scale for pain (VAS scale).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) administration of Nab paclitaxel and cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab paclitaxel</intervention_name>
    <description>Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2)</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>10.5 mg/m2</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Informed consent as documented by signature&#xD;
&#xD;
          -  ≥18 years,&#xD;
&#xD;
          -  psychologically able to follow the trial procedures&#xD;
&#xD;
          -  with peritoneal carcinomatosis from pancreatic, oesogastric, epithelial ovarian&#xD;
             cancers or primitive peritoneal mesothelioma,&#xD;
&#xD;
          -  ECOG 0, 1 or 2,&#xD;
&#xD;
          -  Life expectancy &gt; 3 months,&#xD;
&#xD;
          -  Not candidate for surgical cytoreduction and IP/HIPEC based on expert&#xD;
             multidisciplinary board&#xD;
&#xD;
          -  who received at least one line of chemotherapy and for whom standard therapies have&#xD;
             been exhausted or not feasible. patients with residual disease following the first&#xD;
             line of therapy or Following secondary debulking are eligible.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Predominant extra-peritoneal metastases at the discretion of the study team after&#xD;
             discussion at the multidisciplinary board,&#xD;
&#xD;
          -  Bowel obstruction, active gastro-duodenal ulcer or ongoing abdominal infection&#xD;
             (bacterial, viral or fungal),&#xD;
&#xD;
          -  Chemotherapy or surgery within the last two weeks prior to enrollment,&#xD;
&#xD;
          -  Previous intra-abdominal chemotherapy,&#xD;
&#xD;
          -  General or local (abdominal) contra-indications for laparoscopic surgery&#xD;
&#xD;
          -  Known allergy to cisplatin or other platinum-containing compounds or to&#xD;
             nab-paclitaxel,&#xD;
&#xD;
          -  Severe renal impairment (calculated GFR (CKD-EPI) &lt; 60 mL/min/1.73 m2),&#xD;
             myelosuppression (platelet count &lt; 100.000/μl, hemoglobin &lt; 9g/dl, neutrophil&#xD;
             granulocytes &lt; 1.500/ml), International Normalized Ratio (INR) &gt; 2, severe hepatic&#xD;
             (Serum total bilirubin &gt; 1.5 mg/dl), respiratory or neurologic impairment (grade 3),&#xD;
             severe myocardial insufficiency (NYHA class &gt; 2), recent myocardial infarction, severe&#xD;
             arrhythmias,&#xD;
&#xD;
          -  Pregnancy or breastfeeding, women who can become pregnant must ensure effective&#xD;
             contraception.&#xD;
&#xD;
          -  Known or suspected non-compliance, inability to follow the procedures of the study,&#xD;
             e.g. due to language problems, psychological disorders, dementia, etc. of the&#xD;
             participant,&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Intidhar Labidi-Galy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Intidhar Labidi-Galy, MD, PhD</last_name>
    <phone>0041 22 372 4014</phone>
    <email>intidhar.labidi-galy@hcuge.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Raimond, PharmD</last_name>
    <phone>0041 22 37 22 908</phone>
    <email>catherine.raimond@hcuge.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital, Lausanne</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonella Diciolla, MD</last_name>
      <phone>0041 79 55 63 011</phone>
      <email>Antonella.Diciolla@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital, Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Intidhar Labidi-Galy, MD, PhD</last_name>
      <phone>0041 22 372 4014</phone>
      <email>intidhar.labidi-galy@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Raimond, PharmD</last_name>
      <phone>0041 22 37 22 908</phone>
      <email>catherine.raimond@hcuge.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Intidhar Labidi-Galy, MD, PhD</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>oeso-gastric cancer</keyword>
  <keyword>epithelial ovarian cancer</keyword>
  <keyword>primitive peritoneal mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

